This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: E27.4 (Other and unspecified adrenocortical insufficiency) | OMIM: 240200 (Addison disease, autoimmune) | Special Copayment Reduction: V116 (rare disease) |
| B. Synonyms | Hypoaldosteronism, Adrenocortical insufficiency NOS, Adrenal hemorrhage, Adrenal infarction, idiopathic hypoaldosteronism, hyperreninemic hypoaldosteronism |
| C. Adult onset | Adult onset possible — hypoaldosteronism mainly presents in adults, and adrenal hemorrhage and adrenal infarction occur as complications of severe systemic illness (sepsis, anticoagulant use, etc.); chronic adrenocortical insufficiency (Addison disease) can present at any age. |
| 1. History | 1855: first description of adrenocortical insufficiency by Thomas Addison → 1930s: discovery of corticosteroids → 1950s–60s: elucidation of adrenal autoimmune mechanisms → subtype classification and mechanistic research on hypoaldosteronism. |
| 2. Causes | Diverse: autoimmunity, infection (tuberculosis, fungal), adrenal hemorrhage/infarction, infiltrative diseases, drugs (anticoagulants, ketoconazole), congenital enzyme deficiencies, aldosterone synthase deficiency, etc. |
| 3. Genetics | Aldosterone synthase deficiency (CYP11B2 variants, autosomal recessive). Congenital adrenal hypoplasia (NR0B1/DAX1 variants, X-linked). ACTH resistance (MC2R variants). Familial hypoaldosteronism, etc. |
| 4. General epidemiology | Prevalence of primary adrenocortical insufficiency (Addison disease) approx. 93–140/million; prevalence in Korea approx. 10–15/million, lower than in Western countries. Adrenal hemorrhage occurs in 0.3–1.8% of patients on anticoagulant therapy and rarely in neonates after traumatic delivery. |
| 5. Pathophysiology | Destruction/hypofunction of the adrenal cortex → decreased cortisol and aldosterone secretion → compensatory ACTH increase (primary), reduced feedback (secondary). In hypoaldosteronism, impaired Na⁺ retention and decreased K⁺ excretion → hyperkalemia and hyponatremia. |
| 6. Symptoms | Chronic: fatigue, weight loss, anorexia, nausea, muscle weakness, hypotension, hyponatremia, hyperkalemia, skin hyperpigmentation (primary). Acute (adrenal crisis): shock, vomiting, abdominal pain, decreased consciousness. |
| 7. Signs | Orthostatic hypotension, hyperpigmentation (oral mucosa, skin creases), electrolyte abnormalities (Na↓, K↑), hypoglycemia, eosinophilia. In adrenal crisis, hypotension/shock and abdominal tenderness. |
| 8. Screening | Morning serum cortisol (baseline), ACTH stimulation test (250μg cosyntropin), serum ACTH, serum aldosterone-to-renin ratio. Adrenal autoantibody (21-hydroxylase antibody) testing. |
| 9. Diagnosis | ACTH stimulation test (adrenal hypofunction diagnosed if peak cortisol <18μg/dL). Serum ACTH, aldosterone, and renin measurement. Adrenal CT/MRI. 21-hydroxylase autoantibodies. Genetic testing (CYP11B2, NR0B1, etc.). |
| 10. Treatment | Chronic: hydrocortisone (15–25mg/day), fludrocortisone (0.05–0.2mg/day) if needed. Acute adrenal crisis: hydrocortisone 100mg IV followed by continuous infusion of 200–400mg/24 hours, aggressive normal saline fluid therapy. |
| 11. Prognosis | With hormone replacement therapy, most maintain a near-normal quality of life. Fatal if adrenal crisis is not treated immediately. Main causes of death: adrenal crisis, cardiovascular complications. Monitoring for osteoporosis and metabolic syndrome due to long-term steroid therapy is needed. |
| 12. Prevention | Education on stress-dose increase (sick day rules). Prescription of a steroid emergency kit (hydrocortisone injection). Wearing an adrenal crisis alert bracelet recommended. Monitoring of adrenal function in patients on anticoagulant therapy. |
| 13. References | Bornstein SR et al. Diagnosis and Treatment of Primary Adrenal Insufficiency (2016) and 9 others |
The history of adrenocortical insufficiency begins in 1855, when the British physician Thomas Addison published On the Constitutional and Local Effects of Disease of the Supra-Renal Capsules. He was the first to systematically describe a clinical syndrome characterized by extreme weakness, weight loss, skin hyperpigmentation, and hypotension, and confirmed at autopsy that these symptoms were associated with destruction of the adrenal glands (then referred to as the 'supra-renal capsules'). The disease subsequently came to be called 'Addison's disease' and was used as a synonym for primary chronic adrenocortical insufficiency.
Initially, destruction by adrenal tuberculosis was the most common cause, but from the early 20th century, with the spread of antibiotics and improved tuberculosis control, autoimmune adrenocortical insufficiency became the main cause in Western countries. In the 1930s, the chemical structures of adrenocortical hormones were elucidated and cortisone was synthesized, shifting the treatment paradigm. In 1949, Philip Hench and Edward Kendall's research applying cortisone to rheumatoid arthritis earned the Nobel Prize in Physiology or Medicine, and glucocorticoids became widely recognized as hormones indispensable for life.
Aldosterone was first isolated and identified in 1953 by Sylvia Simpson and James Tait, and was established as a mineralocorticoid central to the regulation of sodium-potassium homeostasis. Hypoaldosteronism is defined as decreased aldosterone secretion or reduced aldosterone action, and began to be studied as an independent clinical entity from the 1950s–60s. In particular, the paradoxical finding of low aldosterone despite high renin, observed in patients with diabetic nephropathy or chronic kidney disease, was classified as hyporeninemic hypoaldosteronism, which became an important subtype of the E27.4 category.
Adrenal hemorrhage and adrenal infarction are adrenal vascular events associated with severe sepsis (especially meningococcemia, i.e., Waterhouse-Friderichsen syndrome), anticoagulant therapy, thromboembolism, neonatal trauma, and the like. They had been reported sporadically as autopsy findings since the 17th century, but only gained clinical attention from the mid-20th century. Rupert Waterhouse in 1911 and Carl Friderichsen in 1918 independently and systematically described bilateral adrenal hemorrhage and acute adrenal crisis in meningococcal sepsis, a condition still called Waterhouse-Friderichsen syndrome. In modern times, adrenal hemorrhage occurring in patients on anticoagulant therapy is recognized as one of the most important causes.
In ICD-10, E27.4 is the code covering 'other and unspecified adrenocortical insufficiency'; as distinct from primary Addison disease (E27.1), tuberculous primary adrenocortical insufficiency (E27.1), and secondary/tertiary adrenocortical insufficiency (E27.3), hypoaldosteronism, adrenal hemorrhage, adrenal infarction, and the like are classified here. In Korea, it is designated as Special Copayment Reduction V116, and care is supported within the rare disease management system.
The causes of adrenocortical insufficiency NOS and related subtypes included in E27.4 can be broadly divided into destruction/dysfunction of the adrenal gland itself and adrenal vascular events. Autoimmune adrenocortical insufficiency accounts for approximately 70–90% of primary adrenocortical insufficiency in Western countries and arises through a mechanism in which autoantibodies against the 21-hydroxylase (CYP21A2) protein destroy the adrenal cortex. It often occurs as part of autoimmune polyendocrine syndrome type 1 (APS-1, AIRE gene variants) or type 2 (APS-2).
Among infectious causes, tuberculosis has historically been the most important and remains a non-negligible cause in countries with a high incidence of tuberculosis (including Korea). Opportunistic infections such as cytomegalovirus (CMV), Cryptococcus, and histoplasmosis in patients with HIV/AIDS are also causes. Infiltrative diseases include metastatic cancer (lung and breast cancer are common), lymphoma, sarcoidosis, and amyloidosis; in these cases, adrenal insufficiency generally appears only when more than 90% of both adrenal glands are destroyed.
The main causes of adrenal hemorrhage include anticoagulant therapy (heparin, warfarin, direct oral anticoagulants), thrombocytopenia (immune thrombocytopenic purpura, heparin-induced thrombocytopenia), sepsis (especially Waterhouse-Friderichsen syndrome due to meningococcemia), trauma, traumatic delivery in neonates, and antiphospholipid antibody syndrome. Bilateral, extensive hemorrhage can progress to acute adrenal crisis, which is life-threatening.
Adrenal infarction is caused by embolism or thrombosis of the adrenal arteries and can occur in antiphospholipid antibody syndrome, thrombotic thrombocytopenic purpura (TTP), and hypercoagulable states prone to thromboembolism. Bilateral adrenal infarction is rare, but once it occurs, it results in permanent loss of adrenal function.
Hyporeninemic hypoaldosteronism occurs mainly in patients with diabetic nephropathy, chronic kidney disease, cyclosporine therapy, or long-term NSAID use, and is particularly common in elderly diabetic patients. Inhibitors of the renin-angiotensin-aldosterone system (RAAS) (ACE inhibitors, ARBs, direct renin inhibitors) and heparin are causes of iatrogenic hypoaldosteronism. Aldosterone synthase deficiency (CYP11B2 variants) is a rare congenital cause in which cortisol secretion is normal but aldosterone is selectively deficient. Pseudohypoaldosteronism is target-organ resistance due to defects in the aldosterone receptor or downstream signaling.
Aldosterone synthase is a cytochrome P450 enzyme encoded by the CYP11B2 gene (8q24.3) that catalyzes the final step converting corticosterone to aldosterone in the zona glomerulosa of the adrenal cortex. Pathogenic CYP11B2 variants are inherited in an autosomal recessive manner and are classified into type I (corticosterone methyloxidase deficiency type I, CMO-I) and type II (CMO-II). In CMO-I, 18-hydroxylation is impossible, while in CMO-II there is a defect in 18-oxidation, and accumulation of 18-hydroxycorticosterone is observed. Clustered occurrence due to a founder effect has been reported in Middle Eastern and Iranian Jewish populations.
The X-linked form of congenital adrenal hypoplasia is caused by variants in the NR0B1 (DAX1) gene (Xp21.2), presents in the neonatal period or early infancy, and involves deficiency of both glucocorticoids and mineralocorticoids. Autosomal recessive forms are caused by variants in NROB2 (SHP), NR5A1 (SF-1), CDKN1C (IMAGe syndrome), and others. ACTH resistance (familial glucocorticoid deficiency, FGD) is caused by variants in the MC2R (ACTH receptor) or MRAP (melanocortin 2 receptor accessory protein) gene and is characterized by glucocorticoid deficiency with preserved mineralocorticoids.
Genetic susceptibility to autoimmune adrenocortical insufficiency is associated with HLA-DR3 and HLA-DR4 haplotypes and CTLA-4 and PTPN22 polymorphisms. In autoimmune polyendocrine syndrome type 1 (APS-1, AIRE gene variants), adrenocortical insufficiency is a major component, occurring at a frequency of approximately 70–80%. Variants in the AIRE (autoimmune regulator) gene (21q22.3) impair the formation of central tolerance to self-antigens in the thymus, causing various endocrine autoimmune diseases.
Pseudohypoaldosteronism type 1 (PHA1) has two forms: an autosomal dominant form (mild, limited to the kidney) caused by variants in NR3C2 (mineralocorticoid receptor), and an autosomal recessive form (multiorgan, severe) caused by variants in the SCNN1A, SCNN1B, and SCNN1G genes, which make up the epithelial sodium channel (ENaC) of the collecting duct. Pseudohypoaldosteronism type 2 (Gordon syndrome, PHA2) is characterized by hyperkalemia and hypertension due to variants in the WNK1, WNK4, KLHL3, and CUL3 genes.
The prevalence of primary adrenocortical insufficiency (including primary Addison disease) is reported at approximately 93–144 per million in Western countries, with an annual incidence of 4.7–6.2 per million. Relatively high prevalence has been reported in Nordic countries such as Norway and Denmark, associated with the high proportion of autoimmune adrenocortical insufficiency. The prevalence in Korea is estimated to be lower than in Western countries (approx. 10–30 per million), reflecting differences in HLA haplotype distribution and ethnic differences in the incidence of autoimmune diseases. However, in Korea, where tuberculosis prevalence is relatively high, the proportion of cases caused by tuberculous adrenocortical destruction may be relatively higher than in Western countries.
The incidence of adrenal hemorrhage is very low on a population basis, but it occurs at a meaningful frequency in certain high-risk groups. The frequency of adrenal hemorrhage in patients receiving anticoagulant therapy is reported at approximately 0.3–1.8%, and Waterhouse-Friderichsen syndrome is not uncommon in patients with sepsis, especially meningococcemia. Traumatic adrenal hemorrhage in neonates has been reported in association with macrocephalic delivery, trauma before cesarean section, instrumental delivery, and the like.
Hyporeninemic hypoaldosteronism is observed in a substantial proportion of patients with diabetic nephropathy, and hyperkalemia due to mild hypoaldosteronism is commonly found in elderly patients with type 2 diabetes. In terms of sex distribution, autoimmune adrenocortical insufficiency is 2–3 times more common in women, whereas adrenal hemorrhage and hypoaldosteronism show no clear sex difference. Age of onset is the 30s–50s for the autoimmune form; adrenal hemorrhage occurs in critically ill patients and neonates, and hypoaldosteronism mainly in elderly diabetic patients.
The adrenal cortex is divided into three zones: the zona glomerulosa mainly secretes aldosterone, the zona fasciculata cortisol, and the zona reticularis adrenal androgens. Cortisol is regulated by the hypothalamic-pituitary-adrenal axis (HPA axis), a hierarchical control system of hypothalamic CRH → pituitary ACTH → adrenocortical cortisol secretion. Aldosterone is regulated mainly by the renin-angiotensin system (RAS) and serum K⁺ concentration, with ACTH having only a secondary influence.
As adrenocortical hypofunction or destruction progresses, cortisol and aldosterone secretion decrease. In primary adrenocortical insufficiency, loss of negative feedback due to decreased cortisol causes a marked compensatory rise in ACTH (often >200pg/mL), and this excess ACTH, together with pro-opiomelanocortin (POMC)-derived melanocyte-stimulating hormone (MSH), causes hyperpigmentation of the skin and oral mucosa. In secondary and tertiary adrenocortical insufficiency (pituitary and hypothalamic causes), ACTH is low or normal, so hyperpigmentation does not occur.
In aldosterone deficiency, sodium reabsorption decreases and potassium and hydrogen ion excretion are reduced in the distal tubule and collecting duct. As a result, hyponatremia, hyperkalemia, and non-anion gap metabolic acidosis develop, and circulating plasma volume decreases, which can progress to hypotension and, in severe cases, shock. Cortisol deficiency causes decreased hepatic gluconeogenesis, increased insulin sensitivity, and dysregulated immune function, resulting in hypoglycemia, immune activation, and uncontrolled inflammatory responses.
The adrenal gland receives a rich blood supply and is one of the organs with the highest blood flow per unit weight in the body. Its structural features — numerous small arteries entering radially from the capsule, forming an extensive capillary network in the adrenal cortex, and then converging into a single central vein — contribute to its vulnerability to hemorrhage. When disseminated intravascular coagulation (DIC) due to sepsis, anticoagulant overdose, or intravascular thrombus formation acts on this central vein and the adrenal veins, intra-adrenal pressure rises abruptly, causing hemorrhagic infarction. When bilateral extensive hemorrhage damages more than 80–90% of adrenal function, acute adrenal crisis appears.
Because symptoms of chronic adrenocortical insufficiency progress slowly and are nonspecific, diagnosis is commonly delayed by an average of 1–3 years. The most common and prominent symptom is chronic fatigue and lethargy, present in more than 90% of patients. Muscle weakness, weight loss (average 3–5kg), anorexia, nausea and vomiting, and abdominal pain are also common. Hypotension (especially orthostatic hypotension) may present as dizziness or syncope on standing even when blood pressure is within the normal range. In primary adrenocortical insufficiency, salt craving appears as a characteristic symptom of aldosterone deficiency, and a pathological, strong desire for salt has been reported.
Neuropsychiatric symptoms are also common, with reports of cognitive decline, decreased concentration, depressed mood, anxiety, and apathy. These symptoms can be difficult to distinguish from hypothyroidism or depression. In women, decreased adrenal androgens can cause loss of axillary and pubic hair and decreased libido. Hypoglycemia occurs frequently, particularly in children and in diabetic patients on insulin therapy, due to loss of the anti-insulin action of cortisol, and nocturnal hypoglycemia is a problem.
Adrenal crisis is a medical emergency in patients with adrenocortical insufficiency, triggered by precipitating factors such as infection, surgery, trauma, or emotional stress. Main symptoms include severe nausea/vomiting, abdominal pain, extreme generalized weakness and decreased level of consciousness, high fever, and hypotension or shock. If untreated, it can lead to coma and death. The annual incidence is reported at approximately 5–8 episodes per 100 patients with primary adrenocortical insufficiency on hormone replacement therapy.
In hypoaldosteronism, hyperkalemia is the main problem; in mild cases it presents as muscle weakness and fatigue, but in severe cases cardiac arrhythmias (including ventricular fibrillation) and ascending paralysis can occur. Headache, nausea, and confusion due to hyponatremia accompany it, and in chronic cases, lowered blood pressure and postural dizziness appear. Kussmaul respiration due to metabolic acidosis may occur.
The most characteristic physical sign of primary adrenocortical insufficiency is skin hyperpigmentation. It results from excessive stimulation by ACTH and POMC-derived α-MSH and is especially prominent in sun-exposed areas, friction areas (knees, elbows, finger joints), lips and oral mucosa, gingiva, palmar creases, scars, and around the genitals. In secondary adrenocortical insufficiency, ACTH secretion is reduced, so hyperpigmentation does not occur; rather, the skin is pale and body hair is reduced.
Blood pressure measurement reveals orthostatic hypotension (a decrease of 20mmHg or more in systolic or 10mmHg or more in diastolic blood pressure on changing from sitting to standing), and in severe cases hypotension persists even in the supine position. The pulse may show (compensatory) tachycardia. Loss of axillary and pubic hair may be observed in women, accompanied by changes in physique due to weight loss. In pediatric patients, growth failure may appear as a sign.
Blood tests show hyponatremia (approx. 90% of patients with primary adrenocortical insufficiency), hyperkalemia (approx. 65%), hypoglycemia (especially in children and secondary forms), and mild non-anion gap metabolic acidosis. Complete blood count may show mild normocytic anemia, eosinophilia, and relative lymphocytosis. Renin concentration is markedly elevated in primary adrenocortical insufficiency, while hypoaldosteronism shows a hyporeninemic or hyperreninemic pattern. Adrenal CT shows adrenal atrophy in autoimmune causes, adrenal enlargement and calcification in tuberculous causes, and increased density and enlargement of the adrenal glands in adrenal hemorrhage.
Screening for adrenocortical insufficiency is performed when clinical suspicion arises; large-scale population screening is not performed. Morning serum cortisol measurement is used as the first-line screening test: a serum cortisol below 3μg/dL at 8 a.m. (the diurnal peak of cortisol secretion) strongly suggests adrenal hypofunction, and 18μg/dL or higher indicates normal adrenal function. In the gray zone between 3 and 18μg/dL, dynamic stimulation testing is needed.
In high-risk groups for autoimmune adrenocortical insufficiency (family members of patients with APS-1 or APS-2, those positive for 21-hydroxylase antibodies), proactive surveillance with regular morning cortisol and ACTH stimulation tests is recommended. Screening for hypoaldosteronism is performed in patients with unexplained hyperkalemia or metabolic acidosis by measuring serum aldosterone and plasma renin activity (PRA) or direct renin concentration. In neonates with suspected congenital aldosterone synthase deficiency, serum electrolyte abnormalities (hyperkalemia, hyponatremia) and the serum aldosterone/18-hydroxycorticosterone ratio are measured early.
In neonates from families with hereditary adrenocortical insufficiency such as aldosterone synthase deficiency (CYP11B2 variants), serum electrolytes and cortisol are measured early after birth, with genetic testing if needed. In particular, the management protocol for a second newborn in a family whose eldest child is affected should be carried out in consultation with a specialized center for congenital adrenal hypoplasia. For the ACTH stimulation test, the standard-dose (250μg) or low-dose (1μg) test is applied selectively depending on the situation.
The ACTH stimulation test (cosyntropin test) is the key test for confirming adrenocortical insufficiency. Cosyntropin (tetracosactide) 250μg, a synthetic ACTH analog, is given intravenously (standard dose) or subcutaneously/intramuscularly, and serum cortisol is measured after 30 and 60 minutes. A normal response is a peak cortisol of 18μg/dL (500nmol/L) or higher; below this threshold, adrenal hypofunction is diagnosed. The standard-dose test is useful for diagnosing primary and severe secondary adrenocortical insufficiency, but because false negatives are possible in mild or recent-onset secondary adrenocortical insufficiency, a low-dose (1μg) ACTH test or insulin tolerance test (ITT) may additionally be needed.
The insulin tolerance test induces hypoglycemia (blood glucose <40mg/dL) with an insulin injection and then checks the cortisol response; it is the standard test for evaluating the entire HPA axis, but caution is needed because it is dangerous in patients with cardiovascular disease, epilepsy, and the elderly. The metyrapone test and CRH stimulation test are used to distinguish the lesion location (hypothalamus vs. pituitary).
Serum ACTH measurement is essential for distinguishing primary (high, >200pg/mL) from secondary (low or normal) adrenocortical insufficiency. Serum aldosterone and plasma renin activity (PRA) or direct renin concentration are measured to calculate the aldosterone-to-renin ratio and characterize the pathophysiology of hypoaldosteronism. Urinary free cortisol, serum DHEAS (adrenal androgen), and serum 17-hydroxyprogesterone are also used as diagnostic adjuncts. 21-hydroxylase (CYP21A2) autoantibody and anti-adrenal antibody testing is important for confirming an autoimmune cause; if positive, evaluation for associated APS-1/APS-2 is needed.
Adrenal CT evaluates adrenal size, density, and morphology and is used to differentiate causes. Bilateral adrenal atrophy is seen in autoimmune forms, enlargement and calcification in tuberculous forms, and high-density enlargement in hemorrhage. Adrenal MRI is better than CT for tissue characterization and is used to evaluate infiltrative lesions. Genetic testing (NGS panel, CYP11B2, NR0B1, AIRE, MC2R, MRAP, etc.) is performed in pediatric patients with a suspected hereditary cause, patients with a family history, and patients with autoantibody-negative primary adrenocortical insufficiency. Nuclear medicine studies (I-NP-59 adrenocortical scan) are also sometimes used to evaluate functional adrenal tissue.
The treatment principle for chronic adrenocortical insufficiency is physiological replacement of the deficient hormones. Glucocorticoid replacement: hydrocortisone is recommended as the first-line agent, generally 15–25mg per day divided into 2–3 doses (e.g., 10mg in the morning + 5mg at noon + 5mg in the afternoon). Prednisolone (3–5mg/day) or dexamethasone (0.25–0.375mg/day) may also be given, but they do not mimic the diurnal pattern of cortisol well and carry a higher risk of adverse effects. Recently, modified-release hydrocortisone (Plenadren), which mimics the physiological pulsatile secretion pattern of cortisol, has been in use in some countries.
Mineralocorticoid replacement: fludrocortisone 0.05–0.2mg/day is given to patients with primary adrenocortical insufficiency (when accompanied by aldosterone deficiency). In secondary adrenocortical insufficiency, aldosterone secretion via the RAS is often preserved even when ACTH secretion is reduced, so fludrocortisone may not be needed. The appropriate dose is adjusted based on serum K⁺, Na⁺, plasma renin activity, and blood pressure. Adrenal androgen replacement: DHEA (dehydroepiandrosterone) 25–50mg/day may be used selectively in female patients and may help improve quality of life, libido, and fatigue, but it is not recommended as standard therapy.
Adrenal crisis is a medical emergency requiring immediate treatment. Give hydrocortisone 100mg intravenously immediately, followed by 200–400mg by continuous IV infusion over the next 24 hours (or 50–100mg in divided doses every 4–6 hours). At the same time, give 1L of normal saline (0.9% NaCl) within 1 hour as aggressive fluid therapy, together with dextrose infusion to correct hypoglycemia. Identify and treat the precipitating factor (infection, trauma, etc.). At hydrocortisone doses of 100mg or more, there is sufficient mineralocorticoid action, so additional fludrocortisone is unnecessary.
Because cortisol demand rises sharply in patients with adrenocortical insufficiency during physical stress (fever, surgery, trauma, childbirth), education on dose adjustment according to the sick day rule is essential. Mild fever (38–39℃): twice the usual dose; severe fever (39℃ or higher) or inability to take oral medication due to vomiting: hydrocortisone 100mg IM or IV. Prescribe an emergency injection kit (hydrocortisone 100mg injection) to all patients and provide self-administration training. The preoperative 'stress-dose protocol' is adjusted according to the extent of surgery.
Since the introduction of hormone replacement therapy, the prognosis of adrenocortical insufficiency has improved markedly. Life expectancy in appropriately treated patients is nearly similar to that of the general population, but some studies report a standardized mortality ratio (SMR) in patients with primary adrenocortical insufficiency of 1.5–2.0 times that of the general population. The main causes of death are adrenal crisis, infection, and cardiovascular disease. Adrenal crisis occurs 5–8 times per 100 patients per year and is fatal if not properly treated, so preventive education is important.
The prognosis of acute adrenocortical insufficiency due to adrenal hemorrhage and adrenal infarction depends on the severity of the underlying condition (sepsis, excessive anticoagulation, etc.). Adrenal function may recover to some extent after recovery, but when extensive destruction has occurred, permanent adrenocortical insufficiency may remain.
Even in patients on hormone replacement therapy, reduced quality of life compared with the general population is reported, and fatigue, depression, cognitive decline, and the like are sometimes not fully corrected. This is understood to be because current hormone replacement therapy cannot fully reproduce the pulsatile secretion pattern and tissue-specific distribution of physiological cortisol. The risk of adverse effects from long-term steroid replacement, such as osteoporosis, hypertension, metabolic syndrome, and susceptibility to infection, must be monitored. Fludrocortisone overdose can cause hypertension, hypokalemia, and lower-extremity edema.
Primary prevention of autoimmune adrenocortical insufficiency is currently difficult. However, in families with autoimmune risk factors (such as siblings of patients with APS-1/APS-2), preclinical diagnosis through autoantibody screening is possible. Adrenal destruction by tuberculosis can be prevented through tuberculosis prevention (BCG vaccination, early treatment of active tuberculosis). During anticoagulant therapy, maintain the appropriate therapeutic range (e.g., INR target) to minimize the risk of adrenal hemorrhage, and intensify coagulation monitoring especially during trauma, surgery, and infection. In families with confirmed hereditary adrenocortical insufficiency, early diagnosis and preparation are possible through prenatal genetic testing and genetic counseling.
To prevent adrenal crisis in patients already diagnosed with adrenocortical insufficiency, the following are thoroughly implemented. First, prescribe emergency hydrocortisone injection (100mg) to all patients and teach self-administration. Second, educate both patients and caregivers on dose adjustment according to the sick day rule. Third, recommend wearing a medical alert bracelet stating 'adrenal insufficiency' or 'steroid dependence.' Fourth, during surgery, procedures, or childbirth, the attending medical staff must always be informed of the adrenocortical insufficiency so that the stress-dose protocol is applied. Influenza and pneumococcal vaccinations reduce the risk of infection-induced adrenal crisis.
To minimize complications of long-term hormone replacement therapy, maintain the lowest effective dose and periodically perform bone density (DXA) testing to detect and treat osteoporosis early. Regularly monitor blood pressure, serum electrolytes, and blood glucose, and manage cardiovascular risk factors. Manage depression, cognitive decline, and the like through psychological support and, if needed, psychiatric consultation. Strengthen patient education to increase self-management ability, and establish a system of regular follow-up with a specialized endocrinology or rare disease clinic.